Biologically Active Small Molecules

A high-affinity, lipophilic, non-selective ligand of the &beta-adrenergic receptors (Kis = 0.114 and 0.

A high-affinity, lipophilic, non-selective ligand of the &beta-adrenergic receptors (Kis = 0.114 and 0.

A high-affinity, lipophilic, non-selective ligand of the &beta-adrenergic receptors (Kis = 0.114 and 0.

A high-affinity, lipophilic, non-selective ligand of the &beta-adrenergic receptors (Kis = 0.114 and 0.

An agonist of both nAChR and mAChR receptors, with reported Ki values ranging from 10 to 10,000 nM for different receptors and different preparations used to study responses mediated by nAChR and mAChR, including smooth muscle contraction, gut

An agonist of both nAChR and mAChR receptors, with reported Ki values ranging from 10 to 10,000 nM for different receptors and different preparations used to study responses mediated by nAChR and mAChR, including smooth muscle contraction, gut

A more lipid soluble form of carbaprostacyclin may more readily enter cells to activate PPAR&delta may be more amenable for dietary formulations.

A more lipid soluble form of carbaprostacyclin may more readily enter cells to activate PPAR&delta may be more amenable for dietary formulations.

A more lipid soluble form of carbaprostacyclin may more readily enter cells to activate PPAR&delta may be more amenable for dietary formulations.

A more lipid soluble form of carbaprostacyclin may more readily enter cells to activate PPAR&delta may be more amenable for dietary formulations.

Carbaprostacyclin is a stable analog of PGI2. When infused in rabbits or dogs, it inhibits ex vivo platelet aggregation, but the effect persists only 10 minutes after termination of the infusion.

An affinity probe which allows carbaprostacyclin to be detected in complexes with transmembrane receptors and/or nucleic or protein binding partners.